288 related articles for article (PubMed ID: 31676303)
1. Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.
Li J; Woodward M; Perkovic V; Figtree GA; Heerspink HJL; Mahaffey KW; de Zeeuw D; Vercruysse F; Shaw W; Matthews DR; Neal B
JACC Heart Fail; 2020 Jan; 8(1):57-66. PubMed ID: 31676303
[TBL] [Abstract][Full Text] [Related]
2. Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.
Li J; Neal B; Perkovic V; de Zeeuw D; Neuen BL; Arnott C; Simpson R; Oh R; Mahaffey KW; Heerspink HJL
Kidney Int; 2020 Sep; 98(3):769-777. PubMed ID: 32470492
[TBL] [Abstract][Full Text] [Related]
3. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
[TBL] [Abstract][Full Text] [Related]
4. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC
Am J Kidney Dis; 2021 Jan; 77(1):23-34.e1. PubMed ID: 32971190
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
[TBL] [Abstract][Full Text] [Related]
6. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; de Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B
Circulation; 2018 Jul; 138(5):458-468. PubMed ID: 29526832
[TBL] [Abstract][Full Text] [Related]
8. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
[TBL] [Abstract][Full Text] [Related]
9. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
Tye SC; Jongs N; Coca SG; Sundström J; Arnott C; Neal B; Perkovic V; Mahaffey KW; Vart P; Heerspink HJL
Cardiovasc Diabetol; 2022 Sep; 21(1):194. PubMed ID: 36151557
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW
J Am Coll Cardiol; 2022 Nov; 80(18):1721-1731. PubMed ID: 36302584
[TBL] [Abstract][Full Text] [Related]
11. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
Vaduganathan M; Sattar N; Xu J; Butler J; Mahaffey KW; Neal B; Shaw W; Rosenthal N; Pfeifer M; Hansen MK; Januzzi JL
J Am Coll Cardiol; 2022 Feb; 79(5):432-444. PubMed ID: 35115099
[TBL] [Abstract][Full Text] [Related]
12. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
Sen T; Li J; Neuen BL; Neal B; Arnott C; Parikh CR; Coca SG; Perkovic V; Mahaffey KW; Yavin Y; Rosenthal N; Hansen MK; Heerspink HJL
Diabetologia; 2021 Oct; 64(10):2147-2158. PubMed ID: 34415356
[TBL] [Abstract][Full Text] [Related]
13. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
[TBL] [Abstract][Full Text] [Related]
14. Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.
Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Li Q; Jardine M; Oh R; Heerspink HL; Perkovic V
J Am Soc Nephrol; 2019 Nov; 30(11):2229-2242. PubMed ID: 31530577
[TBL] [Abstract][Full Text] [Related]
15. Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.
Oshima M; Neal B; Toyama T; Ohkuma T; Li Q; de Zeeuw D; Heerspink HJL; Mahaffey KW; Fulcher G; Canovatchel W; Matthews DR; Perkovic V
J Am Soc Nephrol; 2020 Oct; 31(10):2446-2456. PubMed ID: 32694216
[TBL] [Abstract][Full Text] [Related]
16. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
Matsutani D; Sakamoto M; Kayama Y; Takeda N; Horiuchi R; Utsunomiya K
Cardiovasc Diabetol; 2018 May; 17(1):73. PubMed ID: 29788955
[TBL] [Abstract][Full Text] [Related]
17. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.
Sezai A; Sekino H; Unosawa S; Taoka M; Osaka S; Tanaka M
Cardiovasc Diabetol; 2019 Jun; 18(1):76. PubMed ID: 31167663
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.
Fletcher RA; Arnott C; Rockenschaub P; Schutte AE; Carpenter L; Vaduganathan M; Agarwal R; Bakris G; Chang TI; Heerspink HJL; Jardine MJ; Mahaffey KW; Neal B; Pollock C; Jun M; Rodgers A; Perkovic V; Neuen BL
J Am Heart Assoc; 2023 Jul; 12(13):e028516. PubMed ID: 37345834
[TBL] [Abstract][Full Text] [Related]
19. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B
Circulation; 2019 May; 139(22):2591-2593. PubMed ID: 30882240
[No Abstract] [Full Text] [Related]
20. Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial.
Doi Y; Hamano T; Yamaguchi S; Sakaguchi Y; Kaimori JY; Isaka Y
Diabetes Obes Metab; 2023 Oct; 25(10):2944-2953. PubMed ID: 37385955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
